Review Article
Plasticity and mTOR: Towards Restoration of Impaired Synaptic Plasticity in mTOR-Related Neurogenetic Disorders
Table 2
Mechanisms of impaired synaptic plasticity, mTOR dysregulation, and therapeutic targets.
| | Condition | Gene (chromosome) | Mechanism of impaired synaptic plasticity impairment | mTOR physiology | Therapeutic targets |
| | TSC | TSC 1 (9) or
TSC2 (16) | ↓mGluR-LTD | ↑mTOR | mTOR antagonists
mGluR 5 agonist |
| | NF1 | NF1 (17) | ↓LTP↑GABA | ↑mTOR | Ras antagonists
ERK antagonists |
| | FXS | FMR1 (X) | ↑mGluR-LTD | ↑mTOR | mGluR5 antagonists
mGluR5/mGluR1 genetic reduction
GABAA receptor agonist
PLC/GSK3 antagonist (lithium)
AMPA receptor agonist
MMP 9 antagonist |
| | PTHS | PTEN (10) | ↓LTP | ↑mTOR | mTOR antagonists |
| | EIF4E-associated autism | EIF4E (4) | unknown | Downstream of mTOR | None developed |
|
|
